系统综述与Meta分析:血管活性药物治疗1型肝肾综合征
该系统综述与Meta分析检索了MEDLINE、EMBASE、PubMed和Cochrane注册库,纳入12项随机对照试验共700例1型肝肾综合征患者,评估血管活性药物的疗效与安全性。特利加压素联合白蛋白逆转HRS1优于单用白蛋白或安慰剂(RR 2.54,95%CI 1.51-4.26),但死亡率获益不明确,且不良事件风险显著。
要点
- 特利加压素联合白蛋白逆转HRS1优于单用白蛋白或安慰剂(RR 2.54,95%CI 1.51-4.26)。
- 特利加压素总体死亡率获益不明确(RR 0.79,95%CI 0.63-1.01),敏感性分析后关系减弱。
- 去甲肾上腺素可有效逆转HRS1,但相关试验规模小且未设盲。
核心结论
- 特利加压素在实现HRS1逆转方面优于安慰剂,但死亡率获益较不明确。
- 特利加压素与显著不良事件相关,但输注方案可能耐受性更好。
- 仍持续需要安全有效的肝肾综合征治疗方案。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(OvidSP)、EMBASE、PubMed和Cochrane注册库中的随机对照试验。
- 纳入报告HRS1药物治疗疗效和不良事件的随机对照试验,比较血管活性药物与安慰剂/无治疗,或两种活性药物。
- 共纳入12项随机对照试验,入组700例HRS1患者。
主要发现
- 特利加压素联合白蛋白逆转HRS1的频率高于单用白蛋白或安慰剂(RR 2.54,95%CI 1.51-4.26)。
- 去甲肾上腺素可有效逆转HRS1,但相关试验规模小且未设盲。
- 特利加压素总体死亡率获益为RR 0.79(95%CI 0.63-1.01),仅纳入低选择偏倚风险试验的敏感性分析削弱该关系(RR 0.87,95%CI 0.71-1.06)。
- 特利加压素治疗存在显著不良事件风险(RR 4.32,95%CI 0.75-24.86)。
关键数值与推荐
- 特利加压素联合白蛋白 vs 单用白蛋白或安慰剂:HRS1逆转RR 2.54(95%CI 1.51-4.26)。
- 特利加压素 vs 对照:死亡率RR 0.79(95%CI 0.63-1.01);敏感性分析(仅低选择偏倚风险试验)RR 0.87(95%CI 0.71-1.06)。
- 特利加压素 vs 对照:不良事件RR 4.32(95%CI 0.75-24.86)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 去甲肾上腺素相关试验规模小且未设盲。
- 特利加压素死亡率获益的敏感性分析仅纳入低选择偏倚风险试验后关系减弱(RR 0.87,95%CI 0.71-1.06)。
- 特利加压素不良事件风险的置信区间宽(RR 4.32,95%CI 0.75-24.86)。
- 仍持续需要安全有效的肝肾综合征治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment. AIM: To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs). METHODS: MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for RCTs reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search terms included: 'hepatorenal syndrome', 'terlipressin', 'noradrenaline', 'octreotide', 'midodrine', 'vasopressin', 'dopamine', 'albumin' and synonyms. Comparison of vasoactive drugs vs. placebo/no treatment, and two active drugs were included. Meta-analysis was performed for HRS1 reversal, creatinine improvement, mortality and adverse events. RESULTS: Twelve RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin led to HRS1 reversal more frequently than albumin alone or placebo (RR: 2.54, 95% CI: 1.51-4.26). Noradrenaline was effective in reversing HRS1, but trials were small and nonblinded. Overall, there was mortality benefit with terlipressin (RR: 0.79, 95% CI: 0.63-1.01), but sensitivity analysis including only trials with low risk of selection bias weakened this relationship (RR: 0.87, 95% CI: 0.71-1.06). Notably, there was a significant risk of adverse events with terlipressin therapy (RR: 4.32, 95% CI: 0.75-24.86). CONCLUSIONS: Terlipressin treatment is superior to placebo for achieving HRS1 reversal, but mortality benefit is less clear. Terlipressin is associated with significant adverse events, but infusion regimens may be better tolerated. There is continued need for safe and effective treatment options for hepatorenal syndrome.
引用
- Gifford FJ, Morling JR, Fallowfield JA, et al. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017. PMID: 28052382. doi:10.1111/apt.13912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。